Upper respiratory tract mucosal immunity for SARS-CoV-2 vaccines.

Fraser, Rupsha; Orta-Resendiz, Aurelio; Mazein, Alexander; Dockrell, David H

Fraser, Rupsha; Orta-Resendiz, Aurelio; Mazein, Alexander; Dockrell, David H.

Afiliação

Fraser R; The University of Edinburgh, Queen's Medical Research Institute, 47 Little France Crescent, Edinburgh, EH16 4TJ, UK. Electronic address: rupsha.fraser@ed.ac.uk.
Orta-Resendiz A; Institut Pasteur, Université Paris Cité, HIV, Inflammation and Persistence Unit, F-75015 Paris, France.
Mazein A; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Belvaux, Luxembourg.
Dockrell DH; The University of Edinburgh, Queen's Medical Research Institute, 47 Little France Crescent, Edinburgh, EH16 4TJ, UK.

Trends Mol Med ; 29(4): 255-267, 2023 04.

Article em En | MEDLINE | ID: mdl-36764906

Assuntos

COVID-19; Vacinas Virais; Humanos; Vacinas contra COVID-19; Imunidade nas Mucosas; COVID-19/prevenção & controle; SARS-CoV-2; Infecções Irruptivas; Vacinação

Palavras-chave

SARS-CoV-2 vaccines; interferon-1; upper respiratory tract mucosal immunity; vaccine breakthrough infections; waning immunity

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vacinas Virais / COVID-19 Limite: Humans Idioma: En Revista: Trends Mol Med Assunto da revista: BIOLOGIA MOLECULAR Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google